Neutrophil/Lyrnphocyte Ratio in Advanced Non-Small Cell Lung Cancer: Correlation with Prognosis and Response to Anti-PD1 Therapy

被引：0
|
作者：
Galata, Domenico [1 ]
Logroscino, Antonio Fabio [1 ]
Misino, Andrea [1 ]
Montagna, Elisabetta Sara [1 ]
Petrillo, Patrizia [1 ]
Ricci, Donata [1 ]
Catino, Annamaria [1 ]
机构：
[1] Clin Canc Ctr Giovanni Paolo Ii, Med Oncol Unit, Bari, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
advanced NSCLC; Neutrophils/Leucocytes ratio; Anti-PD1; therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02c-085
引用
收藏
页码：S1329 / S1330
页数：2
相关论文
共 50 条
  • [1] Imaging of Anti-PD1 Therapy Response in Advanced Non-Small Lung Cancer
    Katz, Sharyn
    Hammer, Mark
    Bagley, Stephen
    Aggarwal, Charu
    Bauml, Joshua
    Langer, Corey
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S553 - S554
  • [2] CD155 expression impairs anti-PD1 therapy response in non-small cell lung cancer
    Jiang, Chang
    Qu, Xiaodie
    Ma, Li
    Yi, Ling
    Cheng, Xu
    Gao, Xiang
    Wang, Jinghui
    Che, Nanying
    Zhang, Hongtao
    Zhang, Shucai
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2022, 208 (02): : 220 - 232
  • [3] Resistance mechanisms in non-small cell lung cancer patients upon anti-PD1 therapy
    Hiltbrunner, S.
    Cords, L.
    Kasser, S.
    Freiberger, S.
    Kreutzer, S.
    Toussaint, N.
    Grob, L.
    Bihr, S.
    Rechsteiner, M.
    Soltermann, A.
    Bodenmiller, B.
    Curioni-Fontecedro, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 195 - 195
  • [4] A Novel Autoantibodies Panel Predicted the Prognosis of Advanced Non-Small Cell Lung Cancer Receiving Anti-PD1 Combined With Chemotherapy
    Dai, L.
    Tan, Q.
    Fan, G.
    Xie, T.
    Shi, Y.
    Han, X.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S315 - S315
  • [5] Complete response to anti-PD1 therapy and chemotherapy in a patient with ALK-rearranged non-small cell lung cancer
    Hu, Haoyue
    Min, Min
    Dai, Hongchun
    Tang, Youpan
    He, Jun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2025, 18 (01): : 37 - 41
  • [6] Lung Microbiota Influence Responses to Anti-PD1 Therapy in a Preclinical Model of Non-small Cell Lung Cancer
    Chang, M.
    Mccormick, C.
    Kwok, B.
    Li, Y.
    Kyeremateng, Y.
    Aktas, A.
    Singh, R.
    Singh, S.
    Li, Q.
    Kugler, M. C.
    Pass, H.
    Sterman, D. H.
    Wu, B. G.
    Segal, L. N.
    Tsay, J. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [7] The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer
    Zhang, Shuling
    Bai, Xueli
    Shan, Fengping
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 80
  • [8] What is the optimal duration, dose and frequency for anti-PD1 therapy of non-small cell lung cancer?
    Kuah, Chii Yang
    Monfries, Robert
    Quartagno, Matteo
    Seckl, Michael J.
    Ghorani, Ehsan
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [9] Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy
    Zeng, Xianghua
    Zhu, Shicong
    Xu, Cheng
    Wang, Zhongyu
    Su, Xingxing
    Zeng, Dong
    Long, Haixia
    Zhu, Bo
    MEDICAL SCIENCE MONITOR, 2020, 26
  • [10] Neutrophil to lymphocyte ratio (NLR) as a predictor of poor prognosis in advanced non-small cell lung cancer
    Cherif, Hela
    Bacha, Saoussen
    Sghaier, Amani
    Habibech, Sonia
    Racil, Hager
    Cheikhrouhou, Sana
    Chaouech, Naouel
    Chabbou, Abdellatif
    Megdiche, Mohamed Lamine
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
12345